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a b s t r a c t
Background and aim: Long-term survival of lung cancer patients with brain metastases (BM)
is very rare. Our aim is to report the characteristics of patients who survived for at least
three years after a BM diagnosis.
Materials and methods: Nineteen lung cancer patients who had survived ≥3 years
after a BM diagnosis were identiﬁed in our database. Seven (37%) had undergone
whole-brain radiotherapy (WBRT) only, ﬁve (26%) BM surgery+WBRT, three (16%) BM
surgery+WBRT+BM radiosurgery, and four (21%) no WBRT (one, surgery; one, radiosurgery;
two, BM surgery+ radiosurgery). Their characteristics were compared with historical data
for 322 lung cancer patients with BM (control group, CG), who had received WBRT between
1986 and 1997.
Results: Median survival from BM in long survivors group was 73 months (in CG – 4 months).
Characteristics comparison: median age 55 vs. 58 (CG), p=0.16; female sex 68% vs. 28% (CG),
p=0.003; RTOG/RPA class 1 – 75% vs. 13% (CG), p=0.00001; adenocarcinoma histology 84%
vs. 24% (CG), p<0.00001; control of primary tumor 95% vs. 27% (CG), p<0.00001; extracranial
metastases 0 vs. 26% (CG), p=0.01; single BM 63% vs. 9% (CG), p=0.00001; surgery of BM 53%vs. 14% (CG), p=0.00001.
Conclusions: Beside prognostic factors already recognized as favorable in patients with BM,
the adenocarcinoma histology and female sex were prevalent in long-term survivors of BM
from lung cancer.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.. Background and aimpproximately 15–30% of lung cancer patients develop brain
etastases (BM), according to epidemiological studies.1,2 The
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incidence is higher in more advanced disease stages and
with small-cell lung carcinoma (SCLC) and adenocarcinoma
histology. There has been an increasing incidence of BM
over the last few decades. A population-based Swedish study
showed that the rate of age-adjusted hospital admissions
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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for BM doubled between 1987 and 2006.2 This increase is
related to the better diagnostic methods available and some
progress in the treatment of locally advanced non-small cell
lung carcinoma (NSCLC). A review of the Radiation Therapy
Oncology Group (RTOG) data showed that longer survival with
locally advanced NSCLC is associated with a higher incidence
of BM.3
Despite advances made in surgery, radiation oncology and
systemic treatments, the prognosis of lung cancer patients
with BM remains dismal. The median survival has not
improved with time and is still about three months.2 Survival
may be increased to 7–13 months in selected patients when
surgery4,5 or stereotactic radiotherapy6 is used to complement
whole-brain radiotherapy (WBRT). WBRT, which is commonly
used in the treatment of BM, has never correlated with
improvement of survival in randomized trials.7,8 However, the
prognosis of patientswith BM is determined by variables other
than therapeutic strategies. RTOG recursive partitioning anal-
ysis (RPA) identiﬁed a good performance status, control of
the primary tumor, no extracranial metastasis, and younger
age as factors associated with improved survival.9 However,
the median survival of these favorable patients is still only
about six months. Therefore, a question arises about the addi-
tional factors to offer chance for long survival in BM from lung
cancer. To answer this question, we searched for long-term
survivors of BM from lung cancer in our database and com-
pared the characteristics of these patients with those of the
whole cohort of patients with BM from lung cancer.
2. Materials and methods
A review of the database at the Department of Radiation
Oncology of the Maria Sklodowska-Curie Memorial Cancer
Centre and Institute of Oncology in Warsaw (Poland) identi-
ﬁed 19 patients (long-term survivors) who had survived for at
least 3 years after the diagnosis of BM from histologically con-
ﬁrmed lung cancer, who had been treated and/or followed up
between 1986 and 2006. Three hundred twenty-two patients
with BM from lung cancerwere treated between 1986 and 1997
and an additional 600 such patients were treated between
1998 and 2006. We do not have complete data for patients
treated between 1998 and 2006, so it is probable that there
were more three-year survivors, but they were not followed up
in our centre. However, for the period between 1986 and 1997,
we had ﬁve such patients. This allows us to speculate that
the proportion of three-year survivors from BM in the entire
cohort of such patients is about 2%. The presence of BM was
conﬁrmed by computed tomography (CT) or magnetic reso-
nance imaging (MRI). The medical records of all 19 patients
were available for review. Their records were compared with
the records of 322 lung cancer patients with BM (the con-
trol group, CG) treated with WBRT between 1986 and 1997.
We chose this control group because of the completeness of
their data in terms of prognostic factors, treatment, and sur-
vival, as the results of their treatments have been published
previously.10
The characteristics of the patients in both groups were
compared with regard to age, sex, Karnofsky performance sta-
tus (KPS), RTOG/RPA class (outline 1),9 histology, control ofdiotherapy 1 6 ( 2 0 1 1 ) 49–53
the primary tumor at the time of BM diagnosis, presence of
extracranial metastasis at the time of BM diagnosis, interval
from diagnosis of the primary tumor to the development of
BM (metachronous vs. synchronous [BM diagnosed within one
month of the primary tumor]), number of BM (single vs. mul-
tiple), the use of surgery in the treatment of BM, and the use
of radical surgery in the treatment of the primary tumor.
Outline 1. RTOG/RPA prognostic classes of patients with
brain metastases.
RTOG/RPA prognostic classes9
Class 1: Patients younger than 65 with control of the
primary tumor and no extracerebral metastases and
Karnofsky performance status (KPS) at least 70%
Class 3: Patients with KPS less than 70%
Class 2: All others
All the patients in the CG underwent WBRT for the man-
agement of BM; 105 (33%) received 20Gy in 4Gy fractions, 183
(57%) received 30Gy in 3Gy fractions, and 32 (10%) received
40Gy in 2Gy fractions. Only 44 (14%) patients had undergone
previous surgery for BM. Stereotactic radiosurgery (SRS) was
not available at that time. Among the 19 long-term survivors,
seven (37%) underwentwhole-brain radiotherapy (WBRT) only,
ﬁve (26%) had BM surgery and WBRT, three (16%) had BM
surgery andWBRT followedby SRS for residual tumor, and four
(21%) had no WBRT at all (one, BM surgery only; one, SRS only;
and two, BM surgery and SRS). The WBRT dose was 30Gy in
10 fractions in 13 patients (81%); three other patients received
different schedules (36Gy in 12 fractions, 37.5 in 15 fractions,
and 56Gy in 28 fractions). The doses of linac-based SRS varied
between 15 and 26Gy in one fraction. The relative frequencies
of the prognostic factors were compared between the control
group and long-term survivors with a 2 test.
Survival was calculated from the date of diagnosis of BM.
It was estimated using the Kaplan–Meier method.
3. Results
3.1. Survival and pattern of failure in long-term
survivors
Themedian survival for 19 long-term survivorswas 73months
(range: 36–137 months), whereas that for the entire cohort of
322 CG patients was four months (p=0.00001). Seven patients
remained alive at the time of the last follow; two of themexpe-
rienced successfully salvaged intracranial recurrence (one
with SRS and one with surgery), both outside the primary
tumor bed. Of the 12 patients who died, six experienced an
intracranial recurrence. For three of them, the brain recur-
rence was successfully salvaged with SRS. The causes of death
of 12 patients were: three, brain relapse; two, progression of
the lung cancer outside the brain; two, second primary (pan-
creatic adenocarcinoma and anaplastic thyroid cancer); one,
stroke in a patient with a history of cerebral vascular inci-
dents preceding WBRT; and four, unknown (at 38, 52, 62, and
68 months of follow-up). In ﬁve of the eight patients diag-
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.2. Comparison of characteristics between long-term
urvivors and control group (CG)he results of comparison of the characteristics of the long-
erm survivors vs. controls are reported in Table 1. There was
signiﬁcant difference in the RTOG/ RPA class distributions
p=0.0001): class 1, 75% vs. 13% in CG; class 2, 25% vs. 67% in
Table 1 – Characteristics of 322 patients from control
group and 19 long-term survivors (patients surviving for









Male 232 (72) 6 (32)
Female 90 (28) 13 (68)
Age (p=0.16)
Median [range] 59 [31–79] 55 [42–71]
<65 years 241 (75) 15 (79)
≥65 years 81 (25) 4 (21)
Histology
SCLC (p=0.0004) 132 (41) 0 (0)
Squamous carcinoma 67 (20) 3 (11)
Adenocarcinoma
(p<0.00001)
76 (24) 15 (84)
Large cell carcinoma 3 (1) 0 (0)
NSCLC without type
speciﬁcation
44 (14) 1 (5)
RTOG/RPA prognostic class (p=0.0001)
Class 1 41 (13) 14 (75)
Class 2 215 (67) 5 (25)
Class 3 66 (20) 0
KPS (p=0.03)
>70 256 (80) 19 (100)
≤70 66 (20) 0
Presence of extracranial metastases (p=0.01)
Yes 83 (26) 0
No 229 (71) 19 (100)
Unknown 10 (3) 0
Control of the primary tumor (p<0.00001)
Yes 88 (27) 18 (95)
No 222 (69) 1 (5)
Unknown 12 (4) 0
Number of BM (p=0.00001)
Single 124 (39) 12(63)
Multiple 190 (59) 7(37)
Unknown 8 (2) 0
Interval from diagnosis of the primary to development of BM
(p=0.44)
Synchronous 147 (46) 7(37)
Metachronous 175 (54) 12(63)
Surgery of BM (p=0.00001)
Yes 44 (14) 10 (53)
No 278 (86) 9 (47)
Surgery in the treatment of the primary (p=0.00001)
Yes 30 (9) 11 (58)
No 292 (91) 8 (42)
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CG. There were no RPA class 3 patients among the long-term
survivors. All the RPA/RTOG class 1 components, except age,
were signiﬁcantly associated with long-term survival. Of the
long-termsurvivors, 68%were female,whereas only 28%of the
CG were female (p=0.003). No patient with BM from SCLC sur-
vived for three years. The histological comparison showed a
high incidence of adenocarcinoma in the long-term survivors
(84% vs. 23% in CG; P<0.00001). The proportion of patients
whose primary tumor was treated surgically was much higher
among the long-term survivors (58% vs. 9% in CG, p=0.00001).
Surgery for BM was also related to long-term survival (53% vs.
14% in CG, p=0.00001).
4. Discussion
We have demonstrated that only about 2% of patients sur-
vived for three years in this entire cohort of patients with BM
from lung cancer. This conﬁrms that the prognosis for patients
with BM from lung cancer is very poor, and that only selected
patients will survive in the long term. Reports of other series
conﬁrm that long-term survivors are rare: 5–13% of patients
live for two years and 2–2.5% for ﬁve years.11–13 In contrast,
the results of aggressive treatment of the primary lung tumors
with surgery or radiochemotherapy and of brain metastases
with surgery or SRS have been reported as promising, with
ﬁve-year survival rates of 11–21%.14–16 Although BM surgery
was also associated with improved survival in our previous
study,10 three-year survival was extremely rare. Some incom-
pleteness in our data should be acknowledged, as stated in
Section 2, sowe cannot exclude the possibility that some addi-
tional patients survived for three years but were not recorded.
However, we do not think that there were many such cases,
because all the patients treated with SRS and practically all
those treated with BM surgery and WBRT, or who deliberately
refused WBRT, were followed up at our institution. Regardless
of the possible bias caused by somemissing data, wewere able
to gather information about the characteristics of long-term
survivors.
The conﬁrmation of recognized favorable prognostic fac-
tors, such as the RTOG/RPA class 1 components, including the
control of the primary tumor, the absence of extracranial dis-
semination, and a good performance status, was expected.
However, the median survival of RPA class 1 patients is only
about 6–7 months. Aggressive local treatment of BM with
surgery or SRS may prolong survival.4–6 Additional factors,
other than the therapeutic strategy used, may relate to long-
term survival. In our group of 19 three-year survivors, about
one-third were treated with WBRT only, which emphasizes
the role of the biology of the tumor and other patient-
dependent factors in survival. In randomized trials, WBRT did
not improve survival,7,8 but did improve intracranial control.
In our series, the limited number of events and the varied
treatment strategies do not allow us to draw any ﬁrm con-
clusions about the relationships between the treatment, the
relapse pattern, and long-term survival.We identiﬁed two additional factors related to long-term
survival in BM from lung cancer: female sex and histologi-
cal type, which are not included in the RTOG/RPA prognostic
classes, enclosing BM from all solid tumors. Female sex
nd ra
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appears to be an independent favorable prognostic factor
in lung cancer patients.17,18 It has also been conﬁrmed as
such in patients treated with radiation19 and in patients
with BM.10,20 Possible explanations of the better progno-
sis in females include the inﬂuence of social, hormonal,
or tumor-related factors. In a recently published study by
McGovern et al.,19 the authors concluded that survival differ-
ences between men and women with NSCLC occur because
the disease develops and progresses differently according to
inherent biological differences between the sexes. For women
with NSCLC, pathology examinations more frequently reveal
an adenocarcinoma than a squamous cell carcinoma. In a
prospective study of 4618 patientswith stage I–IVNSCLCat the
Mayo Clinic, 60% of women and 48% of men had adenocarci-
noma, whereas 22% of women and 32% of men had squamous
cell carcinoma (p<0.01).18 We founda signiﬁcantly higher inci-
dence of adenocarcinoma in long-term survivors (84% vs. 23%
in CG). Adenocarcinoma histology has been associated with
a better prognosis in some series of patients with BM from
lung cancer,21 but not in others.10,22,23 However, long-termsur-
vivors have a predominant adenocarcinoma histology.24 We
hypothesize that some types of BM from lung adenocarci-
noma have different molecular characteristics, which make
them a different and curable clinical entity, as opposed to the
largemajority of BM cases, which appear incurable. Some data
already suggest that the genetics of BM from lung cancer may
affect treatment results. In a study by Gow et al.,25 patients
with epidermal growth factor receptor (EGFR) mutations had
a higher response rate to WBRT than patients with wild-type
EGFR.
No patient with BM from SCLC survived for three years in
our series and no long-term survivors were reported in other
series,11–13 which conﬁrms a particularly poor prognosis of
such patients. This can be explained by the biology of SCLC,
because the occurrence of BM is usually a sign of the progres-
sion of the extracranial disease in these patients.26
In conclusion, long term survival in patients with BM from
lung cancer is rare. Very few selected patients from RTOG/RPA
class 1 may survive in the long-term, and more aggressive
treatment is related to longer survival. However, RTOG/RPA
class 1 and aggressive treatment are not sufﬁcient to ensure
long-term survival. Additional unidentiﬁed factors, probably
indicative of biological differences, which are very likely to be
related to female sex and adenocarcinoma histology, should
be considered. Further research is required to precisely iden-
tify the female patients with BM and/or patients with BM from
adenocarcinoma who have such a favorable prognosis.
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